Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

a patent approval won't move this stock much, if at all.

They won't release a PR for it because this company does not operate and has no money for PR's.

And even if they do.... They have held patents for years. So what? A patent for a device that is unprofitable is worthless.

There will be no merger. That is just a silly rumor being spread on a yahoo message board.

licenses do not bring enough money into Radient's coffers to pay their overdue operational bills from 2011, let alone the lender debt of approximately $20 million.

Today is August 1st and Global Cancer Diagnostics is not offering a $99 test. GCDx needs to get funding before they can offer the test. Without an 8-K for a license agreement, they can't legally START to sell it or even manufacture it.